Has Catherine Anastasopoulou, MD received payments from drug or device companies?

Yes. Drug and device makers reported $108,778 in general payments to Catherine Anastasopoulou, MD across 614 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Catherine Anastasopoulou, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Catherine Anastasopoulou, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Catherine Anastasopoulou, MD

Endocrinology, Diabetes & Metabolism · Elkins Park, PANPI 1225099120

Payments from drug & device makers

$108,778in general payments, 2019–2025

Across 614 payments — averaging $177.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Roche Diagnostics Operations, Inc.$51K
Ascendis Pharma Endocrinology Inc$25K
Sanofi-aventis U.S. LLC$14K
F. Hoffmann-la Roche AG$7K
Amgen$1K
Novo Nordisk$1K
plus $9K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Roche Diagnostics Operations, Inc.	33	$51,401
Ascendis Pharma Endocrinology Inc	26	$25,333
Sanofi-aventis U.S. LLC	56	$13,502
F. Hoffmann-la Roche AG	5	$7,200
Amgen(2 entities)	61	$1,387
Novo Nordisk	60	$1,373
Lilly USA, LLC	61	$1,194
Radius Health, Inc.	29	$964
Corcept Therapeutics	29	$671
Boehringer Ingelheim	18	$405
Bayer	17	$395
AstraZeneca(2 entities)	20	$392
Xeris Pharmaceuticals, Inc.	17	$374
Abbott	8	$345
Medtronic	8	$314
Mannkind Corporation	12	$271
Amphastar Pharmaceuticals, Inc.	13	$267
Merck	15	$259
Novartis	21	$257
Recordati_rare_diseases_inc.	9	$231
Kyowa Kirin, Inc.	8	$220
Pfizer	11	$217
Dexcom, Inc.	8	$189
Insulet Corporation	5	$164
Tandem Diabetes Care, Inc.	4	$125
Almatica Pharma LLC	5	$102
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$95
Astellas Pharma US Inc	4	$86
Shire North American Group Inc	2	$84
Madrigal Pharmaceuticals	2	$70
Neurocrine Biosciences, Inc.	2	$69
Cequr Corporation	3	$68
Ultragenyx Pharmaceutical Inc.	3	$67
Amarin Pharma, Inc.	4	$58
Tolmar, Inc.	3	$52
Johnson & Johnson(2 entities)	3	$52
BD	2	$44
Sequel Med Tech, LLC	2	$39
Harmony Biosciences LLC	1	$37
Rhythm Pharmaceuticals, Inc.	2	$36
Ascensia Diabetes Care US Inc.	1	$31
Amryt Pharma Holdings Ltd	2	$31
BETA Bionics, Inc.	1	$31
Takeda Pharmaceuticals U.S.A., Inc.	1	$26
Clarus Therapeutics Inc.	1	$25
Bigfoot Biomedical Inc	1	$24
Acella Pharmaceuticals, LLC	1	$24
AbbVie	1	$24
Verity Pharmaceuticals Inc.	1	$23
Averitas Pharma Inc.	1	$23
Ipsen Biopharmaceuticals, Inc	1	$22
IBSA Pharma Inc.	1	$21
Embecta Corp.	1	$20
Sanofi US Services Inc.	1	$16
Theracosbio, LLC	1	$14
Currax Pharmaceuticals LLC	1	$14

How this compares

$108,778 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$69,795

Medicare patients

326

Services billed

811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Elkins Park

Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M
Mihaela BiscoveanuPhiladelphia$1.5M
Barbara SimonPhiladelphia$1M
Mitchell LazarPhiladelphia$1M
Vijay BahlPittsburgh$998K
Intekhab AhmedPhiladelphia$926K
Erin KershawPittsburgh$804K
Geraldo SaavedraWhitehall$698K
Arvind CavaleFeasterville Trevose$662K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →